DS-1040b + clopidogrel

DS-1040b + clopidogrel is a **combination therapy** of two drugs: DS-1040b, a small molecule inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa, also known as carboxypeptidase U), and clopidogrel, an established P2Y12 receptor antagonist antiplatelet agent. DS-1040b is under development to enhance fibrinolysis in thromboembolic diseases such as acute ischemic stroke and pulmonary embolism by inhibiting TAFIa, which downregulates fibrinolysis, potentially improving clot resolution when used with standard of care. Clopidogrel inhibits platelet aggregation, reducing the risk of further thrombotic events. The rationale for the combination is to provide dual effects of fibrinolysis enhancement and platelet inhibition, particularly in conditions like acute ischemic stroke or pulmonary embolism, where both clot breakdown and platelet activity are medically relevant[1][3][4].